The overall five-year survival rate for stage 4 (metastatic) lung cancer is about 10.5%, based on the most recent national data from 2016 to 2022. But that single number obscures a wide range of outcomes. Some people live months, others live years, and the type of lung cancer, specific genetic features of the tumor, and overall health all shift the picture dramatically.
What the Overall Numbers Show
Stage 4 means the cancer has spread beyond the lungs to distant parts of the body, such as the bones, brain, liver, or adrenal glands. At diagnosis, roughly half of all lung cancers are already at this stage. The national SEER database, which tracks cancer outcomes across the United States, reports a five-year relative survival rate of 10.5% for distant-stage lung and bronchus cancer. That rate has been climbing steadily over the past decade thanks to newer treatments, and people diagnosed today generally have better odds than those numbers reflect, since survival statistics are always looking backward at patients diagnosed years earlier.
Non-Small Cell vs. Small Cell Lung Cancer
The two main types of lung cancer behave very differently at stage 4, and the distinction matters more than almost anything else for prognosis.
Non-small cell lung cancer (NSCLC) accounts for roughly 80 to 85% of cases. At stage 4, median survival varies widely depending on treatment, but many patients now live well beyond a year, and a meaningful percentage reach the five-year mark. The specifics depend heavily on whether the tumor has certain genetic changes (more on that below).
Small cell lung cancer (SCLC) is less common but far more aggressive. When it reaches the extensive stage (the equivalent of stage 4), median survival is only 6 to 10 months even with standard treatment. Small cell tumors initially respond well to chemotherapy, but they tend to recur quickly, and long-term survival remains uncommon.
How Newer Treatments Have Changed Survival
Two categories of treatment have reshaped the outlook for stage 4 NSCLC in particular: immunotherapy and targeted therapy. If you’re reading survival statistics from before 2015 or so, they don’t reflect what’s possible today.
Immunotherapy
For patients whose tumors produce high levels of a protein called PD-L1 (which about a third of NSCLC tumors do), immunotherapy with a checkpoint inhibitor has become the standard first-line treatment. A large international registry of over 1,050 patients with advanced NSCLC and high PD-L1 levels treated with pembrolizumab outside of clinical trials found a five-year survival rate of 26.9%. Median overall survival in that group was roughly 27.5 months. The landmark clinical trial that established this approach reported a five-year survival rate of 31.9%, a result that was considered unprecedented for advanced lung cancer at the time. These numbers represent a genuine shift: before immunotherapy, five-year survival for stage 4 NSCLC was in the low single digits.
Targeted Therapy
Some NSCLC tumors carry specific genetic mutations that make them vulnerable to targeted drugs. The two most well-known are EGFR mutations and ALK rearrangements, though there are others. Patients who start targeted therapy within the first month after diagnosis have a median survival of about 31 months. Even those who begin targeted treatment later, up to 12 months after diagnosis, still see median survival around 25 months. These drugs can shrink tumors dramatically and keep the disease controlled for extended periods, sometimes years, before the cancer finds a way to resist them.
Not every patient qualifies for these treatments. Immunotherapy works best when PD-L1 levels are high, and targeted therapies only apply when specific mutations are present. For patients without these favorable markers, chemotherapy remains the backbone of treatment, and survival times tend to be shorter.
Factors That Influence Individual Survival
Beyond cancer type and treatment, several personal factors can push survival higher or lower than the averages suggest.
- Performance status. This is a measure of how well you can carry out daily activities. People who are still active and relatively independent at diagnosis consistently live longer than those who are bed-bound or need significant help with basic tasks. Oncologists consider this one of the strongest predictors of how well someone will tolerate treatment and how long they’ll survive.
- Number and location of metastases. A single metastatic site (say, one spot in the brain that can be treated with radiation) carries a better prognosis than cancer that has spread to multiple organs simultaneously.
- Weight loss. Losing more than 5% of body weight before treatment starts is associated with a worse outcome. Maintaining nutrition and body weight matters.
- Sex. Women with lung cancer tend to have slightly better survival than men diagnosed at the same stage.
- Overall health. Pre-existing lung disease, heart problems, or other serious conditions can limit treatment options and worsen prognosis. People in better baseline health are more likely to tolerate aggressive treatment and benefit from it.
Survival Without Treatment
Some people search for this information because treatment isn’t an option, whether due to personal choice, advanced age, or other health problems. Without any systemic treatment, stage 4 lung cancer typically progresses quickly. Median survival for untreated metastatic lung cancer is generally measured in weeks to a few months, though this varies with the speed of the cancer and where it has spread. Palliative care, which focuses on symptom management rather than fighting the cancer itself, can significantly improve quality of life during this time even if it doesn’t extend survival substantially.
Why Averages Don’t Tell the Whole Story
Survival statistics are population-level snapshots. They combine people with fast-growing small cell tumors and slow-growing adenocarcinomas, people who received cutting-edge immunotherapy and people who received only supportive care, 40-year-olds and 85-year-olds. Your individual prognosis depends on the specific biology of your cancer, the treatments available to you, and how your body responds. Two people with the same stage can have wildly different trajectories.
The most useful step after absorbing these numbers is understanding the molecular profile of the specific tumor. Genetic testing of the cancer (not your personal DNA, but the tumor’s DNA) determines whether immunotherapy or targeted therapy is likely to work. That single piece of information can shift expected survival from months to years. If you or someone you know has been diagnosed, asking about biomarker testing and PD-L1 status is one of the most important conversations to have with the oncology team.